(NYSE: BHVN) Biohaven's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.83%.
Biohaven's earnings in 2026 is -$586,841,000.On average, 19 Wall Street analysts forecast BHVN's earnings for 2026 to be -$502,507,555, with the lowest BHVN earnings forecast at -$510,679,024, and the highest BHVN earnings forecast at -$429,795,079. On average, 19 Wall Street analysts forecast BHVN's earnings for 2027 to be -$393,771,137, with the lowest BHVN earnings forecast at -$492,916,275, and the highest BHVN earnings forecast at -$253,285,316.
In 2028, BHVN is forecast to generate -$324,275,893 in earnings, with the lowest earnings forecast at -$486,995,359 and the highest earnings forecast at -$214,587,900.